a much more balanced report than the one from bell potter. Wilsons acknowledged the “low level” evidence currently for device, which is an accurate description. Interested to see comment about resection rate as alternative endpoint in a future FDA trial. That depends on whether fda accepts this endpoint and what the study’s comparator would be. Not easy I reckon, depending on the assumptions in future protocol they make could massively sway sample size, cost, time. 2024 still seems optimistic but you never know.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |